Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Clarus Ventures
AddedFeb 13, 2024
UpdatedJun 28, 2026
Clarus Ventures

Clarus Ventures

Acquired

Clarus Ventures, LLC: A global venture capital firm specializing in biotech, medical devices, and diagnostics.

Location
Cambridge, MA, US
Founded
2005
Firm
Compare
Portfolio
Employees

Investments

Gritstone bio
Gritstone bio
Public

Total Raised

$571.6M

Rounds

10

Series B$93MSeptember 2017
Series A$102MOctober 2015
Path
Path

Total Raised

$26.6M

Rounds

3

Series B$25MFebruary 2017
Cleave Therapeutics
Cleave Therapeutics

Total Raised

$101M

Rounds

4

Series B$37MAugust 2016
Series A$42MNovember 2011
Flowonix Medical
Flowonix Medical

Total Raised

$67M

Rounds

5

Debt Financing$5MJune 2016
Series Unknown$20MNovember 2014
Lumos Pharma
Lumos Pharma
Public

Total Raised

$53.5M

Rounds

4

Series B$34MApril 2016
Astria Therapeutics
Astria Therapeutics
Public

Total Raised

$656.4M

Rounds

18

Series B$32.4MNovember 2013
Series Unknown$9MFebruary 2013
Series A$8MDecember 2011
Series A$14.5MDecember 2010
Series A$39MApril 2010
SFJ Pharmaceuticals
SFJ Pharmaceuticals

Total Raised

$144.5M

Rounds

6

Series Unknown$30MOctober 2013
Private Equity$13MApril 2013
Series Unknown$500kOctober 2012
Private Equity$21MJuly 2012
Private Equity$35MApril 2012
NanoString Technologies
NanoString Technologies
Acquired

Total Raised

$826.4M

Rounds

17

Series Unknown$150kMay 2013
Series E$15.3MDecember 2012
Series D$20MNovember 2011
Pearl Therapeutics
Pearl Therapeutics

Total Raised

$255.5M

Rounds

8

Series Unknown$41.7MApril 2013
Series D$65MNovember 2012
Private Equity$23.3MOctober 2012
Sientra
Sientra
Public

Total Raised

$334.7M

Rounds

8

Series C$65MMarch 2012